Document is current
Any future updates will be listed below
-
Authors
Ko, Kwang Hyun
Baek, Seung-Hun
Bae, Hyun Shik
Kim, Young Mi
Gu, Sun Hwa
Jung, Yu Yeon
Kwak, Eun Hye
Choi, Han-Gyu
Kim, Hwa-Jung
Shim, Tae Sun
Kim, Dong-Ho
Bin Cha, Seung
-
Funding
Funding for this research was provided by:
Korea Health Industry Development Institute (RS-2022-KH128236, RS-2022-KH128243, RS-2022-KH128236, RS-2022-KH128243, RS-2022-KH128243, RS-2022-KH128243, RS-2022-KH128243, RS-2022-KH128236, RS-2022-KH128236)
Korea Drug Development Fund (RS-2024-00337146, RS-2024-00337146, RS-2024-00337146, RS-2024-00337146)
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 9 July 2025
First Online: 22 July 2025
Competing interests
: D.-H.K. is the Chief Executive Officer of the NA Vaccine Institute. K.H.K., H.S.B. and S.B.C. are employees of the NA Vaccine Institute. T.S.S. is an employee of Asan Medical Center. The remaining authors declare no competing interests.
